Kevin Kronner, MD
Urology · Missoula, MTNPI 1215932926
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $647 and has fallen 72.0% since, to $181 in 2025. That places this record below the midpoint for urology clinicians in MT, where the typical reported total is $1,996.
Across 107 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$320
- AbbVie$271
- Pfizer$227
- Johnson & Johnson$204
- Dendreon Pharmaceuticals LLC$193
- Rochester Medical Corporation$134
- plus $725 from 23 others
What the payments were for
- Food & beverage$2,01597%
- Education$593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 13 | $320 |
| AbbVie(2 entities) | 17 | $271 |
| Pfizer | 13 | $227 |
| Johnson & Johnson | 11 | $204 |
| Dendreon Pharmaceuticals LLC | 9 | $193 |
| Rochester Medical Corporation | 7 | $134 |
| Urogen Pharma, Inc. | 6 | $111 |
| Endo Pharmaceuticals Inc. | 4 | $73 |
| 180 Medical, Inc. | 3 | $69 |
| Tolmar Pharmaceuticals, Inc. | 2 | $43 |
| Myovant Sciences Inc. | 2 | $40 |
| Laborie Medical Technologies Corp. | 2 | $37 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Sun Pharmaceutical Industries Inc. | 1 | $35 |
| Ambu Inc. | 1 | $32 |
| Amgen | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Endo USA, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Bayer | 1 | $16 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| Photocure Inc | 1 | $13 |
| Coloplast | 1 | $13 |
| Myriad Genetic Laboratories, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $4 |
How this compares
$2,074 in reported general payments places this provider in the 50th percentile of 45 urology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 57 | $769,805 |
| OrgovyxRelugolix | 13 | $32,252 |
| MyrbetriqMirabegron | 16 | $13,222 |
| Tamsulosin Hcl | 200 | $4,161 |
| Potassium Citrate ErPotassium Citrate | 21 | $1,976 |
| Cefpodoxime Proxetil | 172 | $643 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 28 | $385 |
| Cephalexin | 44 | $332 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $229 |
| Levofloxacin | 194 | $177 |
| Finasteride | 11 | $129 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 103 | $125 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $320 | $783,02873 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $22 | $32,25213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 45 urology providers in Montana.
Other urology in Missoula
- Garrick SimmonsMissoula$16K
- Jeffrey RedshawMissoula$4K
- Karl WestenfelderMissoula$4K
- Matthew MundingMissoula$3K
- Christopher WicherMissoula$2K
- Jason ReynoldsMissoula$2K
- Christopher FukudaGreat Falls$19K
- Morris JessopGreat Falls$12K
- Jason SkenazyBozeman$12K
- Amy McKerrowKalispell$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.